CSIMarket
 

Allakos Inc   (NASDAQ: ALLK)
Other Ticker:  
 

Allakos Inc 's

Competitiveness



 
 

ALLK Sales vs. its Competitors Q1 2025



Comparing the current results to its competitors, Allakos Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, slower than the combined decrease of the ALLK's competitors by -3.62 %, recorded in the same quarter.

List of ALLK Competitors





Revenue Growth Comparisons




Net Income Comparison


Allakos Inc recorded a net loss, despite income increase by most of its competitors of 0 %

<<  ALLK Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Allakos Inc Contracts

Allakos Reports Promising Phase 1 Results for Subcutaneous AK006 A Breakthrough in Allergy Therapy

October 10, 2024
Allakos Reports Promising Phase 1 Results for Subcutaneous AK006: A Breakthrough in Allergy Therapy In a significant advancement for the treatment of mast cell-related diseases, Allakos Inc. has announced the successful results of its Phase 1 clinical trial assessing the bioavailability and safety of subcutaneously administered AK006 in healthy volunteers. This novel therapeutic candidate targets mast cell activation and has shown considerable promise, setting the stage for its potential application in treating chronic spontaneous urticaria (CSU).The study revealed that AK006 administered via subcutaneous injection exhibited approximately 77% bioavailability, indicating a robust absorption and subsequent eff...





Publicly Traded Peers of Allakos Inc




Vaccinex Inc
Share Performance



-11.00%
This Year



Vaccinex Inc
Profile

Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.

More about Vaccinex Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.868 mill. $ -0.600 mill. $ -18.634 mill.


Gilead Sciences Inc
Share Performance



+0.49%
30 Days



Gilead Sciences Inc
Profile

Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.

More about Gilead Sciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 140,217.096 mill. $ 28,735.000 mill. $ 5,965.000 mill.


Regeneron Pharmaceuticals Inc
Share Performance



-48.18%
One Year



Regeneron Pharmaceuticals Inc
Profile

Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.

More about Regeneron Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 62,245.312 mill. $ 14,085.700 mill. $ 4,499.300 mill.


Amgen Inc
Share Performance



+0.67%
30 Days



Amgen Inc
Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ 5,933.000 mill.


Astrazeneca Plc
Share Performance



0.00%
Over The Past 5 Days



Astrazeneca Plc
Profile

AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.

More about Astrazeneca Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 112,167.220 mill. $ 45,811.000 mill. $ 5,961.000 mill.


Biocryst Pharmaceuticals Inc
Share Performance



+26.14%
One Year



Biocryst Pharmaceuticals Inc
Profile

Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.

More about Biocryst Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,911.518 mill. $ 503.485 mill. $ -53.470 mill.


Mirati Therapeutics Inc
Share Performance



-0.47%
Over The Past 5 Days



Mirati Therapeutics Inc
Profile

Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.

More about Mirati Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,815.094 mill. $ 38.191 mill. $ -725.878 mill.


Abbvie Inc
Share Performance



+12.98%
One Year



Abbvie Inc
Profile

AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.

More about Abbvie Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 340,915.080 mill. $ 57,367.000 mill. $ 4,203.000 mill.


Lyra Therapeutics Inc
Share Performance



0.00%
Over The Past 5 Days



Lyra Therapeutics Inc
Profile

Lyra Therapeutics Inc is a biotechnology company that focuses on developing drug-delivery systems for patients with ear, nose, and throat (ENT) diseases. They utilize their proprietary technology, known as XTreo, to precisely deliver therapeutics to targeted areas within the ENT region. Their business model revolves around developing and commercializing these unique drug-delivery solutions to address unmet medical needs in the ENT field.

More about Lyra Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 595.766 mill. $ 1.185 mill. $ -79.530 mill.


Merus N v
Share Performance



+0.92%
30 Days



Merus N v
Profile

Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.

More about Merus N v 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,803.559 mill. $ 54.732 mill. $ -277.344 mill.


Spyre Therapeutics Inc
Share Performance



+25.57%
This Quarter



Spyre Therapeutics Inc
Profile



More about Spyre Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5.523 mill. $ - mill. $ -208.934 mill.


Whitehawk Therapeutics Inc
Share Performance



0.00%
One Year



Whitehawk Therapeutics Inc
Profile



More about Whitehawk Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 78.667 mill. $ 20.536 mill. $ 45.887 mill.


Adagene Inc
Share Performance



+21.25%
This Quarter



Adagene Inc
Profile

Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.

More about Adagene Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 109.199 mill. $ 0.103 mill. $ -33.424 mill.


Adc Therapeutics Sa
Share Performance



+172.73%
This Quarter



Adc Therapeutics Sa
Profile

Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.

More about Adc Therapeutics Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 353.768 mill. $ 75.817 mill. $ -149.842 mill.


Affimed N v
Share Performance



0.00%
30 Days



Affimed N v
Profile

Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.

More about Affimed N v 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 9.268 mill. $ -118.651 mill.


Alx Oncology Holdings Inc
Share Performance



-3.01%
30 Days



Alx Oncology Holdings Inc
Profile

Alx Oncology Holdings Inc's business model is centered around the development and commercialization of innovative cancer therapeutics.

More about Alx Oncology Holdings Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 26.520 mill. $ - mill. $ -130.023 mill.


Adlai Nortye Ltd
Share Performance



-55.34%
One Year



Adlai Nortye Ltd
Profile



More about Adlai Nortye Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 65.447 mill. $ 5.000 mill. $ -104.871 mill.


Aravive Inc
Share Performance



-68.96%
This Year



Aravive Inc
Profile

Aravive Inc operates on a business model that focuses on developing and commercializing innovative therapies to treat life-threatening diseases by targeting key signaling pathways.

More about Aravive Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.051 mill. $ 6.995 mill. $ -39.847 mill.


Atossa Therapeutics Inc
Share Performance



+6.91%
30 Days



Atossa Therapeutics Inc
Profile

Atossa Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for breast conditions and oncology.

More about Atossa Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 114.690 mill. $ - mill. $ -26.344 mill.


Biomea Fusion Inc
Share Performance



-47.70%
This Year



Biomea Fusion Inc
Profile

Biomea Fusion Inc operates on a business model focused on the development of precision medicine for cancer treatments. They leverage advanced genomic technologies to identify and understand specific gene fusions that drive cancer growth. By developing targeted therapies, they aim to improve patient outcomes and revolutionize cancer treatment.

More about Biomea Fusion Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 70.690 mill. $ - mill. $ -99.365 mill.


Bristol myers Squibb Company
Share Performance



+1.97%
Over The Past 5 Days



Bristol myers Squibb Company
Profile

Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.

More about Bristol myers Squibb Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 97,022.233 mill. $ 47,636.000 mill. $ 5,437.000 mill.


Bolt Biotherapeutics Inc
Share Performance



-57.24%
One Year



Bolt Biotherapeutics Inc
Profile

Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.

More about Bolt Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 242.307 mill. $ 3.638 mill. $ -63.347 mill.


Blueprint Medicines Corporation
Share Performance



+1.07%
30 Days



Blueprint Medicines Corporation
Profile

The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.

More about Blueprint Medicines Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 8,603.808 mill. $ 562.121 mill. $ -155.729 mill.


Checkpoint Therapeutics inc
Share Performance



+57.20%
This Quarter



Checkpoint Therapeutics inc
Profile

Checkpoint Therapeutics Inc is a biopharmaceutical company that develops and commercializes immune-targeted therapies for the treatment of cancer. The company mainly focuses on acquiring, developing, and commercializing targeted immunotherapy and immuno-oncology products. Through collaborations and strategic partnerships, Checkpoint Therapeutics aims to bring innovative and effective therapies to patients while creating value for shareholders.

More about Checkpoint Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 254.848 mill. $ - mill. $ -56.507 mill.


Cogent Biosciences Inc
Share Performance



+39.10%
This Year



Cogent Biosciences Inc
Profile

Cogent Biosciences Inc operates on a biopharmaceutical business model focused on the development and commercialization of precision therapies for patients with genetically driven diseases. The company utilizes its proprietary expertise in discovering, designing, and developing therapies to target specific genetic alterations with the aim of improving patient outcomes and quality of life. By leveraging their scientific knowledge and strategic partnerships, Cogent Biosciences Inc aims to advance precision medicine and address unmet medical needs in the field of genetic diseases.

More about Cogent Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,229.391 mill. $ - mill. $ -269.497 mill.


Cytomx Therapeutics Inc
Share Performance



+145.28%
This Year



Cytomx Therapeutics Inc
Profile

Cytomx Therapeutics Inc is a biopharmaceutical company that focuses on developing novel antibody-based therapeutics for the treatment of cancer. They utilize proprietary Probody technology to create highly specific and targeted therapies that have the potential to improve treatment outcomes for patients with cancer.

More about Cytomx Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 226.592 mill. $ 147.557 mill. $ 41.603 mill.


Cytodyn inc
Share Performance



+128.76%
One Year



Cytodyn inc
Profile

Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.

More about Cytodyn inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 390.832 mill. $ - mill. $ -7.086 mill.


Day One Biopharmaceuticals Inc
Share Performance



0.00%
Over The Past 5 Days



Day One Biopharmaceuticals Inc
Profile

Day One Biopharmaceuticals Inc operates with a business model focused on developing targeted therapies for patients with rare genetic diseases and cancer. They aim to leverage their expertise in precision medicine and drug discovery to create innovative treatments that address unmet medical needs. Their approach involves identifying genetic mutations and developing therapies tailored specifically to target these mutations and improve patient outcomes.

More about Day One Biopharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 738.488 mill. $ 161.922 mill. $ -79.136 mill.


Deciphera Pharmaceuticals Inc
Share Performance



+0.87%
30 Days



Deciphera Pharmaceuticals Inc
Profile

Deciphera Pharmaceuticals Inc's business model revolves around the research, development, and commercialization of precision medicines for the treatment of cancer and other serious diseases.

More about Deciphera Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,236.262 mill. $ 174.910 mill. $ -190.416 mill.


Effector Therapeutics Inc
Share Performance



-99.98%
One Year



Effector Therapeutics Inc
Profile

Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.

More about Effector Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.001 mill. $ - mill. $ -34.631 mill.


Essa Pharma inc
Share Performance



+7.36%
This Quarter



Essa Pharma inc
Profile

Essa Pharma Inc.'s business model revolves around the development of targeted small molecule therapeutics for the treatment of cancer. The company aims to address the unmet medical needs of patients with advanced and metastatic forms of prostate and breast cancer. By leveraging their expertise in clinical development and precision medicine, Essa Pharma aspires to bring innovative and effective treatments to market, ultimately improving patient outcomes.

More about Essa Pharma inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 77.680 mill. $ - mill. $ -28.496 mill.


Erasca Inc
Share Performance



-43.70%
This Year



Erasca Inc
Profile

Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.

More about Erasca Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 430.556 mill. $ - mill. $ -157.599 mill.


Genprex Inc
Share Performance



0.00%
Over The Past 5 Days



Genprex Inc
Profile

Genprex Inc's business model focuses on the development and commercialization of gene therapies for the treatment of cancer.

More about Genprex Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4.441 mill. $ - mill. $ -19.384 mill.


Gossamer Bio Inc
Share Performance



+63.86%
This Quarter



Gossamer Bio Inc
Profile

Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.

More about Gossamer Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 308.473 mill. $ 124.590 mill. $ -51.238 mill.


G1 Therapeutics Inc
Share Performance



+0.28%
Over The Past 5 Days



G1 Therapeutics Inc
Profile

G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.

More about G1 Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 375.198 mill. $ 58.195 mill. $ -44.770 mill.


Werewolf Therapeutics Inc
Share Performance



-11.48%
30 Days



Werewolf Therapeutics Inc
Profile

Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.

More about Werewolf Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 48.413 mill. $ - mill. $ -72.411 mill.


Ideaya Biosciences Inc
Share Performance



+34.28%
This Quarter



Ideaya Biosciences Inc
Profile

Ideaya Biosciences Inc operates on a precision medicine approach that combines genomics and synthetic lethality to develop targeted cancer therapies. The company focuses on identifying synthetic lethal interactions in cancer and leveraging these insights to discover and develop drugs that selectively target cancer cells. They collaborate with academic institutions and industry partners to advance their therapeutic pipeline and bring innovative treatments to patients in need.

More about Ideaya Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,014.524 mill. $ - mill. $ -307.083 mill.


I mab
Share Performance



+29.75%
One Year



I mab
Profile

The I Mab business model focuses on the development and commercialization of innovative biopharmaceutical products. They specialize in the research and development of novel antibodies and other therapeutic agents to address unmet medical needs. By collaborating with strategic partners and leveraging their expertise in drug discovery and clinical development, I Mab aims to bring transformative treatments to patients globally.

More about I mab's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 382.793 mill. $ - mill. $ -22.230 mill.


Immunogen inc
Share Performance



+5.29%
This Year



Immunogen inc
Profile

Immunogen Inc is a biotechnology company that focuses on the development of antibody-drug conjugates (ADCs) for the treatment of various types of cancer. Their business model is centered around leveraging their proprietary technology platform to create ADCs that deliver potent cancer-killing agents directly to tumor cells. By partnering with pharmaceutical companies, Immunogen aims to advance their ADC candidates through clinical trials and ultimately bring them to market, aiming to improve the lives of cancer patients.

More about Immunogen inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 8,981.436 mill. $ 287.614 mill. $ -73.522 mill.


Immuneering Corporation
Share Performance



+235.66%
This Quarter



Immuneering Corporation
Profile

Immuneering Corp operates on a business model that harnesses the power of big data in the field of biomedicine. Through their proprietary technologies, they analyze vast amounts of biological data to gain insights into disease mechanisms, drug discovery, and patient care. They leverage their expertise to provide pharmaceutical companies and healthcare organizations with actionable information for accelerating the development of new therapeutics and improving clinical outcomes.

More about Immuneering Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 153.843 mill. $ - mill. $ -61.775 mill.


Janux Therapeutics Inc
Share Performance



-11.87%
This Quarter



Janux Therapeutics Inc
Profile

Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.

More about Janux Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,582.486 mill. $ - mill. $ -77.742 mill.


Kinnate Biopharma Inc
Share Performance



+0.76%
Over The Past 5 Days



Kinnate Biopharma Inc
Profile

Kinnate Biopharma Inc is a company that focuses on developing targeted therapies for genetically-defined cancers.

More about Kinnate Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 124.801 mill. $ - mill. $ -127.154 mill.


Kura Oncology Inc
Share Performance



-71.03%
One Year



Kura Oncology Inc
Profile

Kura Oncology Inc is a biotechnology company that focuses on the discovery and development of precision medicines for the treatment of cancer. Their business model revolves around leveraging their expertise in oncology to identify and design small molecule drug candidates that target specific genetic mutations or biomarkers. Through strategic partnerships and collaborations, Kura aims to advance their drug candidates through clinical studies and ultimately commercialize these precision medicines for patients in need.

More about Kura Oncology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 555.959 mill. $ 67.991 mill. $ -181.887 mill.


Eli Lilly And Company
Share Performance



+2.44%
Over The Past 5 Days



Eli Lilly And Company
Profile

Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.

More about Eli Lilly And Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 713,023.032 mill. $ 49,003.200 mill. $ 11,106.400 mill.


Lantern Pharma Inc
Share Performance



+15.08%
30 Days



Lantern Pharma Inc
Profile

Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.

More about Lantern Pharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 37.854 mill. $ - mill. $ -19.877 mill.


Macrogenics Inc
Share Performance



-66.02%
One Year



Macrogenics Inc
Profile

Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.

More about Macrogenics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 99.485 mill. $ 154.050 mill. $ -55.812 mill.


Mural Oncology Plc
Share Performance



+3.11%
This Quarter



Mural Oncology Plc
Profile

Mural Oncology Plc's business model focuses on developing and commercializing innovative cancer therapies. They likely collaborate with research institutes and pharmaceutical companies to acquire promising drug candidates and conduct rigorous clinical trials. Their revenue is generated through licensing, partnerships, and potential product sales, helping provide solutions for patients suffering from various forms of cancer.

More about Mural Oncology Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 42.664 mill. $ - mill. $ -130.734 mill.


Nucana Plc
Share Performance



-95.19%
This Year



Nucana Plc
Profile

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

More about Nucana Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.113 mill. $ - mill. $ -27.632 mill.


Nuvalent Inc
Share Performance



+15.95%
This Quarter



Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,876.831 mill. $ - mill. $ -300.856 mill.


Novartis Ag
Share Performance



+11.97%
One Year



Novartis Ag
Profile

Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.

More about Novartis Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 258,843.160 mill. $ 46,660.000 mill. $ 14,854.000 mill.


Northwest Biotherapeutics Inc
Share Performance



-18.01%
This Year



Northwest Biotherapeutics Inc
Profile

Northwest Biotherapeutics Inc's business model focuses on the development and commercialization of personalized immunotherapy products for the treatment of cancer.

More about Northwest Biotherapeutics Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.303 mill. $ 1.473 mill. $ -85.920 mill.


Nextcure Inc
Share Performance



-42.90%
This Year



Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 13.113 mill. $ - mill. $ -49.523 mill.


Olema Pharmaceuticals Inc
Share Performance



0.00%
Over The Past 5 Days



Olema Pharmaceuticals Inc
Profile

Olema Pharmaceuticals Inc.'s business model focuses on the research, development, and commercialization of innovative cancer therapies.

More about Olema Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 414.317 mill. $ - mill. $ -128.893 mill.


Oncosec Medical Incorporated
Share Performance



-45.66%
30 Days



Oncosec Medical Incorporated
Profile

Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers.

More about Oncosec Medical Incorporated's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.717 mill. $ - mill. $ -29.386 mill.


Oncternal Therapeutics Inc
Share Performance



-82.95%
This Quarter



Oncternal Therapeutics Inc
Profile

Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.

More about Oncternal Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.220 mill. $ 2.161 mill. $ -34.575 mill.


Oric Pharmaceuticals Inc
Share Performance



+18.90%
30 Days



Oric Pharmaceuticals Inc
Profile

Oric Pharmaceuticals Inc's business model focuses on the development and commercialization of innovative therapeutics for the treatment of cancer.

More about Oric Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 813.415 mill. $ - mill. $ -132.857 mill.


Panbela Therapeutics Inc
Share Performance



-39.89%
This Year



Panbela Therapeutics Inc
Profile

Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.

More about Panbela Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.313 mill. $ - mill. $ -27.917 mill.


Pfizer Inc
Share Performance



-11.57%
One Year



Pfizer Inc
Profile

Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.

More about Pfizer Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 146,033.250 mill. $ 62,463.000 mill. $ 7,912.000 mill.


Protagonist Therapeutics inc
Share Performance



+12.51%
This Quarter



Protagonist Therapeutics inc
Profile

Protagonist Therapeutics Inc's business model focuses on the development and commercialization of novel peptide-based therapeutics.

More about Protagonist Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,326.063 mill. $ 207.801 mill. $ 56.193 mill.


Rain Oncology Inc
Share Performance



-52.19%
This Year



Rain Oncology Inc
Profile

Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.

More about Rain Oncology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 126.951 mill. $ - mill. $ -72.260 mill.


Rapt Therapeutics Inc
Share Performance



+428.83%
This Year



Rapt Therapeutics Inc
Profile

Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.

More about Rapt Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,856.836 mill. $ - mill. $ -116.509 mill.


Repare Therapeutics Inc
Share Performance



+18.18%
This Year



Repare Therapeutics Inc
Profile

Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.

More about Repare Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 66.443 mill. $ - mill. $ -127.894 mill.


Sagimet Biosciences inc
Share Performance



+203.06%
One Year



Sagimet Biosciences inc
Profile

Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.

More about Sagimet Biosciences inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 319.056 mill. $ - mill. $ -57.114 mill.


Syndax Pharmaceuticals Inc
Share Performance



0.00%
Over The Past 5 Days



Syndax Pharmaceuticals Inc
Profile

Syndax Pharmaceuticals Inc has a business model centered around developing innovative cancer treatments. They focus on leveraging their expertise in epigenetics and immuno-oncology to create therapies that target specific cancer types. Syndax collaborates with strategic partners and utilizes clinical trials to bring their treatments to market and improve patient outcomes.

More about Syndax Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 846.208 mill. $ 43.722 mill. $ -331.204 mill.


Shattuck Labs Inc
Share Performance



-36.01%
This Year



Shattuck Labs Inc
Profile

Shattuck Labs Inc operates through a platform-based business model, focusing on the development of biotechnology products and solutions. By utilizing its proprietary technology and expertise, the company aims to create innovative therapies targeting various diseases and disorders, ultimately improving patient outcomes. Shattuck Labs Inc collaborates with strategic partners and stakeholders to advance its pipeline, aiming to commercialize its novel treatments and drive growth in the biotech industry.

More about Shattuck Labs Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 39.463 mill. $ - mill. $ -70.608 mill.


Syros Pharmaceuticals Inc
Share Performance



-99.85%
One Year



Syros Pharmaceuticals Inc
Profile

Syros Pharmaceuticals Inc operates based on a business model focused on developing targeted gene control therapies to treat various diseases. The company aims to leverage its gene control platform to identify and exploit unique gene regulatory networks to discover and develop novel therapeutics.

More about Syros Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.354 mill. $ - mill. $ -97.815 mill.


Tg Therapeutics Inc
Share Performance



+4.61%
30 Days



Tg Therapeutics Inc
Profile

TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.

More about Tg Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6,131.516 mill. $ 386.386 mill. $ 39.150 mill.


Theseus Pharmaceuticals Inc
Share Performance



+83.71%
This Quarter



Theseus Pharmaceuticals Inc
Profile

Theseus Pharmaceuticals Inc operates on a business model focused on the development and commercialization of pharmaceutical products.

More about Theseus Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 177.837 mill. $ - mill. $ -56.612 mill.


Tyme Technologies Inc.
Share Performance



-69.83%
One Year



Tyme Technologies Inc.
Profile

Tyme Technologies Inc. is a biotechnology company that operates through the development and commercialization of pharmaceutical products. Their business model focuses on the research, development, and sale of proprietary cancer therapy drug candidates. By leveraging innovative technology and strategic partnerships, Tyme aims to bring novel treatment options to the market, improving patient outcomes and addressing unmet medical needs in the oncology field.

More about Tyme Technologies Inc.'s Market Share

Market Cap. Revenues TTM Net Income TTM
$ 53.505 mill. $ - mill. $ -24.192 mill.


Verastem Inc
Share Performance



-26.96%
This Year



Verastem Inc
Profile

Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.

More about Verastem Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 256.780 mill. $ - mill. $ -148.877 mill.


Xencor Inc
Share Performance



+0.98%
30 Days



Xencor Inc
Profile

Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb? technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.

More about Xencor Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 683.630 mill. $ 127.228 mill. $ -211.056 mill.


Zai Lab Limited
Share Performance



+12.18%
This Quarter



Zai Lab Limited
Profile

Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.

More about Zai Lab Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 36,834.526 mill. $ 418.326 mill. $ -252.070 mill.


Zentalis Pharmaceuticals Inc
Share Performance



-54.33%
This Year



Zentalis Pharmaceuticals Inc
Profile

Zentalis Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of small molecule therapies for the treatment of various types of cancer. Their business model revolves around leveraging their expertise in drug discovery, conducting clinical trials, and ultimately commercializing effective cancer treatments. By leveraging their innovative research and development capabilities, Zentalis aims to address unmet medical needs and improve the lives of cancer patients worldwide.

More about Zentalis Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 98.199 mill. $ - mill. $ -224.186 mill.


Nektar Therapeutics
Share Performance



+162.40%
This Quarter



Nektar Therapeutics
Profile

Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.

More about Nektar Therapeutics's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,294.192 mill. $ 87.248 mill. $ -133.041 mill.


Mannkind Corporation
Share Performance



0.00%
Over The Past 5 Days



Mannkind Corporation
Profile

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.

More about Mannkind Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,219.409 mill. $ 297.595 mill. $ 30.116 mill.


Arvinas Inc
Share Performance



+6.77%
30 Days



Arvinas Inc
Profile

Arvinas Inc's business model revolves around developing novel therapies based on protein degradation technology to address unmet medical needs.

More about Arvinas Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 573.603 mill. $ 426.900 mill. $ -46.600 mill.


Revance Therapeutics Inc
Share Performance



+7.67%
30 Days



Revance Therapeutics Inc
Profile

Revance Therapeutics Inc is a biotechnology company that specializes in developing innovative treatments for medical aesthetic and therapeutic applications. Their business model revolves around researching and developing novel neuromodulator products primarily for the treatment of various aesthetic and therapeutic conditions. The company aims to license or commercialize their products and technologies to generate revenue and advance patient care in collaboration with partners.

More about Revance Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 380.377 mill. $ 247.003 mill. $ -1.629 mill.


Evolus Inc
Share Performance



-4.89%
This Quarter



Evolus Inc
Profile

Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.

More about Evolus Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 619.768 mill. $ 380.295 mill. $ -56.203 mill.


Morphosys Ag
Share Performance



+147.52%
One Year



Morphosys Ag
Profile

Morphosys Ag's business model revolves around the development and commercialization of therapeutic antibodies.

More about Morphosys Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 650.570 mill. $ 266.872 mill. $ -212.502 mill.


Travere Therapeutics Inc
Share Performance



+14.14%
30 Days



Travere Therapeutics Inc
Profile

Travere Therapeutics Inc operates under a business model focused on developing and commercializing therapies for rare diseases. They aim to provide innovative treatments and solutions for patients suffering from these conditions. The company primarily focuses on research, development, and distribution of pharmaceutical products tailored for rare diseases.

More about Travere Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,462.291 mill. $ 273.533 mill. $ -226.710 mill.


Puma Biotechnology Inc
Share Performance



+2.33%
One Year



Puma Biotechnology Inc
Profile

Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.

More about Puma Biotechnology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 175.670 mill. $ 232.709 mill. $ 38.067 mill.


Atea Pharmaceuticals Inc
Share Performance



+10.53%
This Year



Atea Pharmaceuticals Inc
Profile

Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.

More about Atea Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 321.902 mill. $ - mill. $ -169.515 mill.


Myovant Sciences Ltd
Share Performance



+0.11%
Over The Past 5 Days



Myovant Sciences Ltd
Profile

Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.

More about Myovant Sciences Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,613.259 mill. $ 379.112 mill. $ -183.770 mill.


Chimerix Inc
Share Performance



+829.25%
One Year



Chimerix Inc
Profile

Chimerix Inc is a pharmaceutical company that focuses on developing antiviral therapeutics for various diseases. Their business model revolves around conducting research and development to create innovative drug candidates, seeking partnerships and collaborations with other companies to advance their products, and ultimately gaining regulatory approval and commercializing their drugs in the market. By strategically targeting unmet medical needs and leveraging their expertise, Chimerix aims to improve patient outcomes and generate revenue through the successful development and distribution of their antiviral therapeutics.

More about Chimerix Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 763.342 mill. $ 0.212 mill. $ -88.387 mill.


Medicinova Inc
Share Performance



0.00%
Over The Past 5 Days



Medicinova Inc
Profile

Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.

More about Medicinova Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 62.289 mill. $ - mill. $ -11.159 mill.


Xilio Therapeutics inc
Share Performance



0.00%
Over The Past 5 Days



Xilio Therapeutics inc
Profile

Xilio Therapeutics Inc is a biotechnology company focused on developing and commercializing novel immunotherapies to treat cancer.

More about Xilio Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 55.570 mill. $ 9.274 mill. $ -54.303 mill.


Prelude Therapeutics Inc
Share Performance



-29.03%
This Year



Prelude Therapeutics Inc
Profile

Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.

More about Prelude Therapeutics Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 67.407 mill. $ - mill. $ -127.827 mill.


Eqrx Inc
Share Performance



+4.46%
This Quarter



Eqrx Inc
Profile

Eqrx Inc is a pharmaceutical company that focuses on creating affordable and accessible medication. They employ an innovative business model that combines research and development with scientific expertise to develop generic alternatives to the high-priced drugs in the market. By bypassing the traditional pharmaceutical pricing system, Eqrx aims to make essential medications more affordable for patients and healthcare providers.

More about Eqrx Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,133.098 mill. $ - mill. $ -259.623 mill.


Therapeuticsmd Inc
Share Performance



-32.58%
One Year



Therapeuticsmd Inc
Profile

TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.

More about Therapeuticsmd Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 13.862 mill. $ 1.408 mill. $ -3.442 mill.


Legend Biotech Corporation
Share Performance



+17.69%
This Quarter



Legend Biotech Corporation
Profile

Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.

More about Legend Biotech Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 13,999.909 mill. $ 285.143 mill. $ -518.254 mill.


Beigene Ltd
Share Performance



0.00%
Over The Past 5 Days



Beigene Ltd
Profile



More about Beigene Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 366,212.713 mill. $ 3,047.448 mill. $ -240.485 mill.


Organon and Co
Share Performance



-53.78%
One Year



Organon and Co
Profile

Organon and Co's business model revolves around developing and manufacturing pharmaceutical products.

More about Organon and Co 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,569.555 mill. $ 6,294.000 mill. $ 750.000 mill.


Teva Pharmaceutical Industries Limited
Share Performance



+21.54%
This Quarter



Teva Pharmaceutical Industries Limited
Profile

Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.

More about Teva Pharmaceutical Industries Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 19,158.270 mill. $ 16,617.000 mill. $ -1,320.000 mill.


Viatris Inc
Share Performance



+23.66%
This Quarter



Viatris Inc
Profile

Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.

More about Viatris Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11,029.700 mill. $ 14,330.200 mill. $ -3,790.100 mill.


Sanofi
Share Performance



-2.49%
This Quarter



Sanofi
Profile

Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.

More about Sanofi's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 61,975.974 mill. $ 49,599.720 mill. $ 6,292.160 mill.


Innovation Pharmaceuticals Inc
Share Performance



0.00%
30 Days



Innovation Pharmaceuticals Inc
Profile

Innovation Pharmaceuticals Inc operates under a business model focused on pharmaceutical research and development. They strive to innovate and discover novel drug candidates to address unmet medical needs. Through collaborations, partnerships, and internal capabilities, they aim to bring potential therapies through clinical trials and eventually to market.

More about Innovation Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -2.620 mill.


Tonix Pharmaceuticals Holding Corp
Share Performance



0.00%
Over The Past 5 Days



Tonix Pharmaceuticals Holding Corp
Profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.

More about Tonix Pharmaceuticals Holding Corp 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 251.078 mill. $ 10.041 mill. $ -131.926 mill.


Allarity Therapeutics Inc
Share Performance



-81.95%
One Year



Allarity Therapeutics Inc
Profile

Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.

More about Allarity Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 12.039 mill. $ - mill. $ -23.935 mill.


Viracta Therapeutics Inc
Share Performance



0.00%
Over The Past 5 Days



Viracta Therapeutics Inc
Profile

Viracta Therapeutics Inc is a biopharmaceutical company focused on developing targeted therapies for viral-associated cancers. The company aims to advance research, develop innovative treatments, and commercialize products to improve the lives of patients suffering from these types of cancers.

More about Viracta Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.534 mill. $ - mill. $ -43.289 mill.


Biophytis Sa
Share Performance



-25.59%
Over The Past 5 Days



Biophytis Sa
Profile

Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.

More about Biophytis Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 131.738 mill. $ - mill. $ -19.069 mill.


Cadrenal Therapeutics Inc
Share Performance



0.00%
Over The Past 5 Days



Cadrenal Therapeutics Inc
Profile

Cadrenal Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies in the field of renal diseases.

More about Cadrenal Therapeutics Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15.861 mill. $ - mill. $ -10.651 mill.


Nanoviricides inc
Share Performance



-0.70%
This Year



Nanoviricides inc
Profile

Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.

More about Nanoviricides inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 22.597 mill. $ - mill. $ -9.727 mill.


Cns Pharmaceuticals Inc
Share Performance



-98.56%
One Year



Cns Pharmaceuticals Inc
Profile

CNS Pharmaceuticals Inc's business model focuses on developing innovative solutions and treatments for central nervous system diseases.

More about Cns Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.474 mill. $ - mill. $ -15.614 mill.


Abvc Biopharma Inc
Share Performance



+272.22%
This Quarter



Abvc Biopharma Inc
Profile

ABVC Biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of innovative biopharmaceutical products.

More about Abvc Biopharma Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 50.144 mill. $ - mill. $ -6.332 mill.


Immuron Limited
Share Performance



-0.61%
This Year



Immuron Limited
Profile

Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.

More about Immuron Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4.026 mill. $ 1.480 mill. $ -3.787 mill.


Iterum Therapeutics Plc
Share Performance



-3.57%
This Quarter



Iterum Therapeutics Plc
Profile

Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.

More about Iterum Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 36.784 mill. $ - mill. $ -22.564 mill.


Esperion Therapeutics Inc
Share Performance



+24.54%
This Quarter



Esperion Therapeutics Inc
Profile

Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.

More about Esperion Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 243.199 mill. $ 259.574 mill. $ -153.222 mill.


Cellectar Biosciences Inc
Share Performance



-48.65%
This Year



Cellectar Biosciences Inc
Profile

Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.

More about Cellectar Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 227.174 mill. $ - mill. $ -24.543 mill.


Journey Medical Corp
Share Performance



+27.11%
One Year



Journey Medical Corp
Profile

Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.

More about Journey Medical Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 163.252 mill. $ 56.243 mill. $ -8.303 mill.


Abeona Therapeutics Inc
Share Performance



-1.02%
This Year



Abeona Therapeutics Inc
Profile

Abeona Therapeutics Inc is a biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases. Their business model revolves around identifying and acquiring promising technologies, conducting pre-clinical and clinical research, and eventually bringing these therapies to the market. They collaborate with academic institutions, medical centers, and patient advocacy groups to advance their pipeline and provide solutions for currently untreatable genetic disorders.

More about Abeona Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 291.206 mill. $ 4.713 mill. $ -44.185 mill.


Casi Pharmaceuticals inc
Share Performance



-77.52%
One Year



Casi Pharmaceuticals inc
Profile

Casi Pharmaceuticals Inc. operates under a business model that focuses on the development and commercialization of innovative pharmaceutical products. They likely employ a combination of in-house research and development, partnerships, and licensing agreements to bring their products to market. The company may also engage in strategic marketing and distribution partnerships to ensure the successful commercialization of their therapeutics.

More about Casi Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 21.937 mill. $ 28.537 mill. $ -39.258 mill.


Mineralys Therapeutics Inc
Share Performance



+5.48%
This Quarter



Mineralys Therapeutics Inc
Profile

Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.

More about Mineralys Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 778.314 mill. $ - mill. $ -188.513 mill.


Takeda Pharmaceutical Company Limited
Share Performance



+2.06%
This Quarter



Takeda Pharmaceutical Company Limited
Profile

Takeda Pharmaceutical Company Limited operates under a business model that primarily focuses on research, development, and commercialization of innovative pharmaceutical products. They collaborate with various stakeholders across the healthcare industry, including academia, biotechnology companies, and patient advocacy groups, to drive scientific advancements and understand patient needs. By leveraging their expertise, global presence, and strategic partnerships, Takeda aims to make a positive impact on patients' lives while ensuring long-term growth and sustainability.

More about Takeda Pharmaceutical Company Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 23,452.767 mill. $ 29,166.692 mill. $ 986.394 mill.


Johnson and Johnson
Share Performance



+0.59%
30 Days



Johnson and Johnson
Profile

Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.

More about Johnson and Johnson's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 378,379.418 mill. $ 89,331.000 mill. $ 21,810.000 mill.


Merck and Co Inc
Share Performance



-16.08%
This Year



Merck and Co Inc
Profile

Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.

More about Merck and Co Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 210,298.396 mill. $ 63,922.000 mill. $ 17,451.000 mill.




Sources: Allakos Inc and all companies mentioned above in this report


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com